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Abstract  
The disruption of copper homeostasis and the oxidative stress induced by Cu-amyloids are 
crucial features of Alzheimer’s disease pathology. The copper specific N4-tetradendate 
ligands TDMQ20 and 1 are able to fully inhibit in vitro the aerobic oxidation of ascorbate 
induced by Cu-Aβ1-16, even in the presence of 100 molar equivalents of Zn(II) with respect to 
Cu(II), while other ligands with N2O2 or N3O2 coordination spheres failed to do so. This 
essential result indicates that, in addition to metal selectivity, the coordination sphere of 
copper chelators should exhibit a N4-tetradendate motif to be able to reduce an oxidative 
stress in the zinc-rich physiological environment of brain. The N4-scaffolds of these two 
aminoquinoline-based ligands, TDMQ20 or 1, suitable for a square-planar coordination of 
copper(II), allowed them to enhance both the selectivity for copper and also the ability to 
reduce the oxidative stress induced by copper-amyloid in a zinc-rich environment. 
___________________________________________________________________________ 
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 Redistribution and restoration of the homeostasis of metal ions, especially copper, in the 
brain of patients with Alzheimer’s disease (AD) is now considered as a valuable challenge in 
the chemotherapy of this neurodegenerative condition.1 However, zinc element is abundant 
and strictly regulated in the brain to avoid depletion or excess.2 In addition to zinc-protein 
complexes, large amounts of chelatable zinc are located in the cerebral cortex and the limbic 
region, notably in the hippocampal formation, and concentrated within synaptic vesicles of 
glutamatergic neurons where it acts as a modulator of synaptic transmission.2c Zinc 
concentration has been estimated to reach 300 µM in the synaptic cleft system during strong 
stimulation.2,3 The mean copper concentration in human frontal lobe and cerebellum has been 
reported to be in the range of 60-110 µM.4 The zinc/copper ratio can be as high as 10 to 100, 
in glutamatergic neurons.5a Therefore, any attempt to regulate copper homeostasis and to 
inhibit copper-induced oxidative stress in the brain, must take into account this zinc-rich 
environment.5b   
 Therefore, the ligands designed to regulate the homeostasis of redox metal ions in AD 
brains must be copper specific to avoid the perturbation of zinc. As an example of the 
importance of the possible copper/zinc competition, clioquinol has been discarded due to its 
neurotoxicity attributed to zinc chelation.6 As a matter of fact, the metal selectivity of 8-
hydroxyquinoline scaffold is very low.7 To regulate copper homeostasis, chelators should be 
able to transfer copper from its pathological sink, mainly from the copper-amyloid complexes 
(Cu-Aβ), to glutathione which is a physiological provider of copper to copper enzymes,8 even 
in the presence of zinc. In addition, a large excess of zinc should not prevent the ability of 
these copper chelators to inhibit the production of reactive oxygen species (ROS) generated 
by copper loaded amyloids. Moreover, such ligands should have logP values expected for 
membrane crossing, especially the blood brain barrier (BBB).  
 However, among the copper chelators which are currently under investigation, the 
selectivity for copper with respect to zinc is usually not (or poorly) documented,1a except for 
bis-8-aminoquinoline derivatives that are specific copper chelators.9 In this view, some of us 
reported the capacity of a water-soluble negatively charged chelator named L2 (Figure 1) to 
remove copper from copper-loaded Aβ in the presence of zinc in order to illustrate the 
importance of the Cu selectivity on ROS formation.5 This N2O2 chelator, based on a Schiff-
base scaffold, was able to inhibit the reductive activation of dioxygen in the presence of 1 
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molar equivalent (mol equiv) of Zn(II) but failed to stop ROS production in the presence of 5 
mol equiv of Zn(II) during the ascorbate consumption.5a In addition, as pointed out in the 
article, the ligand L2 is not able to cross the BBB (logP = – 3.7). 
 To enhance the efficiency and drugability of copper chelators, we designed a new series 
of neutral N4-tetradendate copper ligands named TDMQ, based on an 8-aminoquinoline 
motif.10 One of these ligands, TDMQ20 (Figure 1), is a specific ligand for copper compared 
to zinc. In the present work, we investigated the ability of TDMQ20 to inhibit the Cu-Aβ 
activation of dioxygen in the presence of a large excess of zinc(II), up to 100 mol equiv. The 
extraction of copper from Cu-Aβ by TDMQ20, as well as the release of copper from Cu-
TDMQ20 in the presence of glutathione, were also evaluated in the presence of zinc, as these 
two discrete steps are required to put back copper into normal physiological circulation. The 
obtained data were compared with that of ligand 1, a bis-8-aminoquinoline chelator 
previously reported to have a very high selectivity for Cu(II) with respect to Zn(II) {log [Kapp 
Cu-L / Kapp Zn-L] > 12}, and to efficiently transfer copper from Cu-Aβ to glutathione in the 
absence of zinc.9  The 8-hydroxyquinoline derivative PBT21c,11 was used as a comparator. A 
detailed experimental section is provided as Supporting Information. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structures of the N4-tetradentate ligands, mono-8-aminoquinoline TDMQ20 and 
bis(8-aminoquinoline) 1, of the N2O2 ligand L2, and of the bi/tridentate 8-hydroxyquinoline 
PBT2. 
 
 The ability of TDMQ20 to extract copper from Cu-Aβ1-16 was evaluated as follows. The 
Cu(II) complex of Aβ1-16 was prepared by incubation of Aβ1-16 and Cu2+ at 20 µM (molar 
ratio = 1/1) in Hepes buffer pH 7.4. One or three mol equiv of Zn2+ were added into the CuII-
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Aβ1-16 solution. One mol equiv of TDMQ20 was then added, and the reaction was monitored 
by UV-visible spectroscopy. The spectrum of the resulting mixture containing Aβ1-16, Cu(II), 
Zn(II) and TDMQ20 was recorded (Figure 2, red trace, full line for 1 equiv of Zn, dashed line 
for 3 equiv of Zn). In both cases, the spectrum exhibited absorbance at 243 nm assigned to 
Cu-TDMQ20 (bright blue trace), but not at 259 and 342 nm, specific wavelengths of the 
TDMQ20 free ligand. In fact, the spectra of the mixture CuII-Aβ1-16 / TDMQ20 in the 
presence of Zn2+ (red traces) were very similar to the arithmetic addition of the spectra of free 
Aβ1-16 and Cu-TDMQ20 (black dashed trace). This result is the same as that obtained in a 
reaction carried out in the absence of zinc (Figure S1, Supporting Information). It therefore 
clearly indicates that 1 mol equiv of TDMQ20 was sufficient to fully demetalate the copper 
loaded amyloid, providing Cu-TDMQ20, in the presence of either 1 or 3 mol equiv of zinc 
with respect to copper. These data indicate that the presence of 3 mol equiv of zinc does not 
interfere with the demetalation of CuII-Aβ1-16 by one equivalent of TDMQ20.  
  
 
 
 
 
 
 
 
 
 
Figure 2. Extraction of copper from CuII-Aβ1-16 using 1 mol equiv of TDMQ20, in the 
presence of 1 or 3 mol equiv of Zn2+ (full red trace, and dashed red trace, respectively) with 
respect to copper. For detailed experimental conditions, see Supporting Information. 
 
 The release of copper from CuII-TDMQ20 in the presence of GSH was then monitored. 
As previously reported, when the Cu(II) complex of the tetradendate ligand 1 was treated by 
glutathione (GSH), GSH acts both as a reducing agent of Cu(II) and as a competitive ligand 
for the generated Cu(I).9c The resulting Cu(I)-glutathione complex is a physiological supplier 
of copper to the apo form of copper proteins.8 However, the role of zinc in this process has 
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not been reported yet. Consequently, the influence of zinc on copper circulation in the 
presence of chelators remained to be established. We decided to monitor, by UV-visible 
spectrometry, the demetalation of CuII-TDMQ20 in the presence of both glutathione and  Zn2+, 
in Hepes buffer, pH 7.4. Firstly, CuCl2 was incubated with TDMQ20 to generate CuII-
TDMQ20, and 1 mol equiv of ZnCl2 was then added. The spectrum of the reaction mixture 
exhibited a maximal absorbance at 243 nm, typical of that expected for CuII-TDMQ20 (Figure 
3, red trace). Upon addition of glutathione (by aliquots of 20 mol equiv with respect to Cu-
TDMQ), the demetalation of Cu-TDMQ was monitored by formation of the free ligand 
TDMQ20 detected at 259 and 342 nm (well-defined isosbestic points are detected at 279 and 
332 nm; no isosbestic point can be detected below 250 nm, due to the own absorbance of 
glutathione and Cu(I)-glutathione at these wavelengths) (Figure 3). The plotting of the 
absorbance at 259 nm as a function of the number of glutathione equivalents (Figure 3, Insert) 
indicate that 80 equiv of glutathione were required to achieve full demetalation of Cu-TDMQ. 
Interestingly, a similar result was observed in the absence of ZnCl2 (Figure S2, Supporting 
Information), indicating that the presence of zinc did not influence the demetalation of Cu-
TDMQ20 by glutathione in these conditions. 
 So, in vitro, TDMQ20 is able to abstract copper from Cu-Aβ1-16  and then to transfer it to 
glutathione, indicating that this N4-tetradendate ligand has the capacity for regulation of 
copper homeostasis in the presence of zinc. 
  
 
 
 
 
  
 
 
 
Figure 3. Extraction of copper from CuII-TDMQ20 by glutathione (GSH) in the presence of 1 
mol equiv of  Zn2+. The spectrum of the free ligand TDMQ20 (dashed black line) is given for 
comparison. Insert: Variation of the absorbance at 259 nm as a function of the number of 
GSH mol equiv with respect to Cu-TDMQ / Zn2+. For detailed experimental conditions, see 
Supporting Information. 
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 The in vitro ROS production mediated by Cu-Aβ1-16 in the presence or in the absence of 
any additive (namely zinc or a putative chelator) can be evaluated based on the kinetics of 
ascorbate oxidation, easily monitored by UV-visible at 265 nm.9c,12,13 We investigated the 
influence of TDMQ20 (and ligands 1 and PBT2 as comparators, structures in Figure 1) on the 
oxidation of ascorbate induced by Cu-Aβ1-16 in the presence of Zn2+. Firstly, a Zn/Cu molar 
ratio equal to 3 was investigated since senile plaques contain roughly 3 times more Zn than 
Cu (25 and 69 µg/g for Cu and Zn, respectively).14 The results are showed in Figure 4. Trace 
(a) shows the ascorbate autoxidation, without any additive. In the presence of CuCl2, 
ascorbate was fully oxidized in only 5 min (trace b). Cu-Aβ1-16 induced ca. 40% of ascorbate 
oxidation in 5 min, and full oxidation occurred in ca. 25 min (trace c). In the presence of 3 
mol equiv of Zn2+, TDMQ20 or ligand 1 drastically inhibited the ascorbate oxidation induced 
by Cu-Aβ1-16, the oxidation of ascorbate in 30 min being only 15-16% in both cases (traces d 
and e, respectively), very close to the ascorbate autoxidation (8%, trace a).  
 
 
 
 
 
 
 
 
 
Figure 4. UV-visible (265 nm) kinetic spectra of ascorbate oxidation under air, in the presence 
of a) no additive (ascorbate autoxidation), b) CuCl2, c) CuCl2/Aβ1-16, 1/1.1, d) CuCl2/Aβ1-
16/ZnCl2/TDMQ20 = 1/1.1/3/1.1, e) CuCl2/Aβ1-16/ZnCl2/1 = 1/1.1/3/1.1, f) CuCl2/Aβ1-
16/ZnCl2/PBT2 = 1/1.1/3/2.2. For detailed experimental conditions, see Supporting 
Information. 
 
 We also performed similar experiments with PBT2, a bi- or tridentate ligand based on 8-
hydroxyquinoline scaffold, that has been developed as a potential AD drug.1c,15 Since the Cu-
PBT2 complex has potentially a metal/ligand stoichiometry = 1/2,16 we therefore used 2.2 mol 
equiv of PBT2 with respect to Cu-Aβ1-16, to avoid the presence of free Cu2+ ions in the 
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solution. With 3 mol equiv of Zn with respect to copper, 89% of ascorbate oxidation was 
observed in 30 min (Figure 4, trace f), close to the 80% value reported in the absence of zinc9c, 
indicating that PBT2 did not inhibit ascorbate oxidation under these reaction conditions. 
 Since both TMDQ20 and compound 1 efficiently inhibited the ascorbate oxidation 
induced by Cu-Aβ1-16 in the presence of 3 mol equiv of Zn2+, we decided to investigate the 
same reaction with a very large excess of zinc, 100 mol equiv of zinc with respect to copper, a 
Zn/Cu ratio that has been proposed to be biologically relevant.5 In these conditions, Cu-Aβ1-16 
induced 48% of ascorbate oxidation in 5 min, and 86% in 10 min (Figure 5, trace a). This is a 
moderate increase of ROS production compared to the result obtained in the absence of zinc 
(trace b, 39% and 63% in 5 min and 10 min, respectively). A previous report indicated that a 
single zinc equivalent had no effect on Cu-Aβ
 
induced ROS production, even though the 
coordination of Zn2+ impacts the Cu(II) and Cu(I) binding sites of Aβ, and may lead to the 
formation of a hetero-bimetallic Cu-Zn-Aβ complex, without release of Cu.17 
 Our result indicates that a 100-fold excess of Zn2+ resulted in the release of a fraction of 
Cu2+ from CuII-Aβ1-16, which is consistent with a higher ascorbate oxidation. So, the presence 
of a local huge excess of zinc with respect to Cu-Aβ may significantly exacerbate the redox 
toxicity of Cu-Aβ in vivo.    
 In order to evidence the fast action of such N4-tetradendate ligands on the kinetics of the 
ascorbate oxidation induced by CuCl2/Aβ1-16/ZnCl2 (1/1/100 molar ratio), we added one of 
these copper chelators, TDMQ20 or 1 (1 mol equiv), after 6.6 min of reaction (Figure 5, 
traces d and e, respectively). In both cases, the oxidation of ascorbate was immediately and 
completely stopped, indicating that stoichiometric amounts of TDMQ20 and 1 were able to 
fully inhibit the ROS production induced by the mixture Cu(II)/Aβ1-16/Zn(II) = 1/1/100. The 
slopes of traces d and e after 6.6 min (∆Abs265 = 0.002 / min) were not significantly different 
to that of ascorbate autoxidation (Figure 4, trace a, ∆Abs265 = 0.003 / min). 
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Figure 5. UV-visible (265 nm) kinetic spectra of ascorbate oxidation under air, in the presence 
of CuCl2/Aβ1-16/ZnCl2 = 1/1/100, then addition of L (1 mol equiv) at 6.6 min (arrow): L = no 
ligand (trace a), L = TDMQ20 (trace d), L = 1 (trace e). The ascorbate oxidation in the 
presence of CuCl2/Aβ1-16, (trace b), or CuCl2 alone (trace c) are given for comparison. The 
increase of absorbance upon addition of TDMQ20 (d) or 1 (e) at 6.6 min, is due to the own 
absorbance of CuII-TDMQ20, or CuII-1 at 265 nm. For detailed experimental conditions, see 
Supporting Information. 
 
 These tetradendate ligands TDMQ20 and 1, that specifically chelate Cu(II) in a N4-square 
planar fashion, are able to immediately and completely stop the in vitro ongoing aerobic 
oxidation of ascorbate induced by Cu-Aβ1-16, even in the presence of 100 mol equiv of Zn(II) 
with respect to copper ions, while the N2O2-tetradentate ligand L2, able to chelate copper with 
metal/ligand stoichiometry = 1/1, was efficient only in the presence of a stoichiometric 
amount of zinc.5 PBT2, whose copper complex has a N3O2 coordination sphere, and a 
metal/ligand stoichiometry = 1/2,16 failed to inhibit oxygen reduction either in the presence or 
in the absence of zinc. 
 These N4-tetradendate ligands TDMQ20 and 1 have a high selectivity for Cu(II) with 
respect to Zn(II) {log [Kapp Cu-L / Kapp Zn-L] > 12},9a,10 much higher than that of Aβ {log 
[Kapp Cu-Aβ / Kapp Zn-Aβ] = 4-5},5b and thus fulfill the criteria for biologically pertinent 
copper chelators mentioned in the introduction. The obtained results indicated that both 
ligands TDMQ20 and 1 have the potential to reduce or inhibit in vivo ROS production 
induced by Cu-Aβ, even in a very rich zinc physiological environment. 
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 In conclusion, such N4-tetradentate copper-specific ligands, like TDMQ20 and 1, are 
suitable for a square-planar scaffold with Cu(II) and have the ability to largely stabilize Cu(II) 
over Cu(I). This structural feature makes them efficient inhibitors of the in vitro ROS 
production induced by Cu-Aβ, including in a zinc-rich physiological environment. Finally, 
the calculated logP values are 2.5 and 3.5, for TDMQ20 and 1,18 respectively, in the optimal 
range expected for crossing the blood-brain barrier.19 The design of copper ligands able to 
counteract metal deregulation and deleterious consequences in AD brain requires a good 
understanding of their coordination properties. Pharmacological studies on TDMQ20 are in 
progress. 
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Captions for Figures 
Figure 1.  Structures of tetradentate mono-8-aminoquinoline TDMQ20 and bis(8-
aminoquinoline 1, of the N2O2 ligand L2 and of the bi/tridentate 8-
hydroxyquinoline PBT2. 
Figure 2.  Extraction of copper from CuII-Aβ1-16 using 1 mol equiv of TDMQ20, in the 
presence of 1 or 3 mol equiv of Zn2+ (full red trace, and dashed red trace, 
respectively) with respect to copper monitored by UV-visible spectrophotometry. 
Figure 3.  Extraction of copper from CuII-TDMQ20 by glutathione (GSH), in the presence 
of 1 mol equiv of  Zn2+, monitored by UV-visible spectrophotometry. The 
spectrum of the free ligand TDMQ20 (dashed black line) is given for 
comparison. Insert: Variation of the absorbance at 259 nm as a function of the 
number of GSH mol equiv with respect to Cu-TDMQ20 / Zn2+. 
Figure 4. UV-visible (265 nm) kinetic spectra of ascorbate oxidation under air, in the 
presence of a) no additive (ascorbate autoxidation), b) CuCl2, c) CuCl2/Aβ1-16, 
1/1.1, d) CuCl2/Aβ1-16/ZnCl2/TDMQ20 = 1/1.1/3/1.1, e) CuCl2/Aβ1-16/ZnCl2/1 = 
1/1.1/3/1.1, f) CuCl2/Aβ1-16/ZnCl2/PBT2 = 1/1.1/3/2.2. 
Figure 5. UV-visible (265 nm) kinetic spectra of ascorbate oxidation under air, in the 
presence of CuCl2/Aβ1-16/ZnCl2 = 1/1/100, then addition of L (1 mol equiv) at 
6.6 min (arrow): L = no ligand (trace a), L = TDMQ20 (trace d), L = 1 (trace e). 
The ascorbate oxidation in the presence of CuCl2/Aβ1-16, (trace b) CuCl2 (trace 
c) are given for comparison. The increase of absorbance upon addition of 
TDMQ20 (d) or 1 (e) at 6.6 min, is due to the own absorbance of CuII-TDMQ20, 
or CuII-1 at 265 nm. 
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N4-tetradentate copper-specific ligands generate Cu(II) square planar complexes and stabilize 
Cu(II) but not Cu(I). This feature makes them able to regulate copper homeostasis and to 
efficiently inhibit the in vitro oxidative stress induced by Cu-Aβ, including in a zinc-rich 
physiological environment like Alzheimer’s disease brain. The design of ligands able to 
counteract copper deregulation and deleterious effects in AD brain must take into account 
their coordination modes. 
 
 
